Heidelberg Pharma AG Income Statement

Financials in millions EUR. Fiscal year is December - November.

Millions EUR. Fiscal year is Dec - Nov.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '25 Nov 30, 2025	Nov '24 Nov 30, 2024	Nov '23 Nov 30, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021
Operating Revenue	1.46	6.85	9.86	18.51	1.75
Other Revenue	5.47	-	-	-	0.28
Revenue	6.93	6.85	9.86	18.51	2.03
Revenue Growth (YoY)	1.21%	-30.53%	-46.75%	810.30%	-76.53%
Cost of Revenue	0.27	1.78	3.25	4.68	4.71
Gross Profit	6.66	5.07	6.61	13.83	-2.68
Selling, General & Admin	7.61	8.46	6.22	5.99	4.48
Research & Development	38.78	21.84	28.07	26.38	18.75
Other Operating Expenses	2.37	-3.4	-0.14	-0.24	-0.07
Operating Expenses	48.76	26.9	34.15	32.13	23.16
Operating Income	-42.1	-21.83	-27.55	-18.29	-25.84
Interest Expense	-0	-0.14	-0.76	-0.84	-0.49
Interest & Investment Income	-	1.42	7.55	0.24	-
Earnings From Equity Investments	-	-	-	-	-0.01
Currency Exchange Gain (Loss)	-	-0.18	-0.46	0.96	0
Other Non Operating Income (Expenses)	0.87	0.12	0.21	0.06	0.09
EBT Excluding Unusual Items	-41.23	-20.6	-21.01	-17.87	-26.26
Gain (Loss) on Sale of Assets	-	0	0.03	0.02	-
Other Unusual Items	-	1.22	0.63	0.07	0.12
Pretax Income	-41.23	-19.38	-20.35	-17.79	-26.14
Income Tax Expense	1.05	-	-	1.92	-
Net Income	-42.28	-19.38	-20.35	-19.7	-26.14
Net Income to Common	-42.28	-19.38	-20.35	-19.7	-26.14
Shares Outstanding (Basic)	47	47	47	37	33
Shares Outstanding (Diluted)	47	47	47	37	33
Shares Change (YoY)	0.14%	0.02%	25.14%	14.56%	8.72%
EPS (Basic)	-0.91	-0.42	-0.44	-0.53	-0.80
EPS (Diluted)	-0.91	-0.42	-0.44	-0.53	-0.80
Free Cash Flow	-31.73	-30.04	-34.61	-9.45	-27.85
Free Cash Flow Per Share	-0.68	-0.65	-0.74	-0.25	-0.86
Gross Margin	96.07%	74.00%	67.01%	74.72%	-131.69%
Operating Margin	-607.34%	-318.71%	-279.41%	-98.81%	-1270.65%
Profit Margin	-609.95%	-282.98%	-206.38%	-106.42%	-1285.20%
Free Cash Flow Margin	-457.72%	-438.64%	-351.07%	-51.03%	-1369.57%
EBITDA	-36.28	-21.1	-26.84	-17.7	-25.2
EBITDA Margin	-	-	-272.20%	-95.63%	-
D&A For EBITDA	5.82	0.73	0.71	0.59	0.64
EBIT	-42.1	-21.83	-27.55	-18.29	-25.84
EBIT Margin	-	-	-279.41%	-98.81%	-
Revenue as Reported	6.93	11.96	16.8	19.86	2.31

Updated Nov 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.